We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The high cost of AstraZeneca’s ovarian cancer treatment Lynparza doesn’t match the uncertainty of its survival benefits, the UK’s healthcare cost agency says.